David Smith, DO
Dermatology · Charleston, SCNPI 1427672260
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,258 of the $11,650 with a category attached, or 62.3%. Boehringer Ingelheim accounts for 88.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $10,454 and has fallen 98.3% since, to $175 in 2025.
Across 36 payments — averaging $323.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$10K
- AbbVie$699
- Johnson & Johnson$264
- E.r. Squibb & Sons, L.L.C.$139
- Dermavant Sciences, Inc.$70
- Sanofi$47
- plus $80 from 3 others
What the payments were for
- Consulting fees$7,25862%
- Travel & lodging$2,90725%
- Food & beverage$1,37612%
- Education$1091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 14 | $10,351 |
| AbbVie | 12 | $699 |
| Johnson & Johnson | 3 | $264 |
| E.r. Squibb & Sons, L.L.C. | 2 | $139 |
| Dermavant Sciences, Inc. | 1 | $70 |
| Sanofi | 1 | $47 |
| UCB, Inc. | 1 | $29 |
| Arcutis Biotherapeutics, Inc. | 1 | $26 |
| Pfizer | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,650 in reported general payments places this provider in the 80th percentile of 203 dermatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx (2 Syringes)Secukinumab | 15 | $104,020 |
| Dupixent PenDupilumab | 19 | $75,221 |
| Dupixent SyringeDupilumab | 13 | $57,340 |
| Clobetasol Propionate | 34 | $1,941 |
| Triamcinolone Acetonide | 65 | $947 |
| Fluorouracil | 15 | $915 |
| Doxycycline Hyclate | 14 | $790 |
| Ketoconazole | 39 | $739 |
| Clindamycin Phosphate | 12 | $458 |
| CiclopiroxCiclopirox Olamine | 11 | $285 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Charleston
- Todd SchlesingerCharleston$1.9M
- Mark SiegelCharleston$120K
- Erin WalkerCharleston$20K
- Alan SnyderCharleston$13K
- Marshall ShulerGreenville$2.6M
- Rebecca SmithFort Mill$2.3M
- Amylynne FrankelSpartanburg$987K
- Marguerite GermainMt Pleasant$200K
- George KeoughPawleys Island$150K
- Christopher MartinAbbeville$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.